Chotigeat Uraiwan, Jirapapa Kesanat, Layangkool Thanarat
Neonatal Unit, Queen Sirikit National Institute of Child Health, Bangkok 10400, Thailand.
J Med Assoc Thai. 2003 Aug;86 Suppl 3:S563-9.
Indomethacin is widely accepted as the treatment for patent ductus arteriosus (PDA) in preterm infants but it has various side effects. Ibuprofen is the alternative treatment and believed to be less likely to induce side effects.
To compare efficacy and side effects of ibuprofen versus indomethacin treatment for symptomatic patent ductus arteriosus (PDA) in preterm infants.
The authors studied 30 infants (gestational age < or = 35 weeks, aged < or = 10 days) who were diagnosed as having symptomatic PDA confirmed by echocardiogram. The infants were randomly assigned to receive three intravenous doses of indomethacin given at 12-hour intervals or three doses of ibuprofen given at 24-hour intervals, starting within ten days of life. The demographic data, rate of clinical closure, need for additional treatment, side effects, complications and the infants' clinical course were recorded within 28 days.
The rate of ductal closure was similar with the two treatment regimes. Ductal closure occurred in 7 of 15 infants given ibuprofen (46.67%) and 10 of 15 infants given indomethacin (66.67%). (Relative risk 0.669; 95% confidence interval, 0.328 to 1.364; p = 0.462) The number of infants who needed a second pharmacologic treatment was not significantly different between the two groups, (6 cases in the ibuprofen group, 5 cases in the indomethacin group) but surgical ligation was performed in two cases in the indomethacin group. There was a significant difference in using the diuretic drug (furosemide) in the indomethacin group (11 cases), compared to the ibuprofen group (3 cases), (p = 0.009). More cases of necrotizing enterocolitis were seen in the indomethacin group (66.67% compared to 40% in the ibuprofen group) but there was no statistically significant difference.
Ibuprofen has the same efficiency as indomethacin for the treatment of symptomatic patent ductus arteriosus in preterm infants and less likely to induce necrotizing enterocolitis and renal toxicity than indomethacin.
吲哚美辛被广泛用作早产儿动脉导管未闭(PDA)的治疗药物,但它有多种副作用。布洛芬是替代治疗药物,据信其诱发副作用的可能性较小。
比较布洛芬与吲哚美辛治疗早产儿有症状动脉导管未闭(PDA)的疗效和副作用。
作者研究了30例婴儿(胎龄≤35周,年龄≤10天),这些婴儿经超声心动图确诊为有症状的PDA。婴儿被随机分配接受每12小时静脉注射一剂,共三剂的吲哚美辛,或每24小时静脉注射一剂,共三剂的布洛芬,在出生十天内开始给药。记录28天内的人口统计学数据、临床闭合率、额外治疗需求、副作用、并发症及婴儿的临床病程。
两种治疗方案的导管闭合率相似。接受布洛芬治疗的15例婴儿中有7例(46.67%)导管闭合,接受吲哚美辛治疗的15例婴儿中有10例(66.67%)导管闭合。(相对危险度0.669;95%置信区间,0.328至1.364;p = 0.462)两组中需要二次药物治疗的婴儿数量无显著差异(布洛芬组6例,吲哚美辛组5例),但吲哚美辛组有2例接受了手术结扎。吲哚美辛组(11例)使用利尿剂(呋塞米)的情况与布洛芬组(3例)相比有显著差异,(p = 0.009)。吲哚美辛组坏死性小肠结肠炎的病例更多(66.67%,而布洛芬组为40%),但无统计学显著差异。
布洛芬在治疗早产儿有症状动脉导管未闭方面与吲哚美辛有相同的疗效,且比吲哚美辛更不易诱发坏死性小肠结肠炎和肾毒性。